High-Loading-Dose Colistin with Nebulized Administration for Carbapenem-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients: A Retrospective Cohort Study
Antibiotics · 21.03.2024 · 13 (3) · 287
DOI: 10.3390/antibiotics13030287 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Antibiotics, online erschienen am 21.03.2024. Verfasst von Wasan Katip und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chiang Mai University.
Abstract (Originalsprache)
Carbapenem-resistant Acinetobacter baumannii (CRAB) infections pose a serious threat, with high morbidity and mortality rates. This retrospective cohort study, conducted at Nakornping Hospital between January 2015 and October 2022, aimed to evaluate the efficacy and safety of a high loading dose (LD) of colistin combined with nebulized colistin in critically ill patients with CRAB pneumonia. Of the 261 patients included, 95 received LD colistin, and 166 received LD colistin with nebulized colistin. Multivariate Cox regression analysis, adjusted for baseline covariates using inverse probability weighting, showed no significant difference in 30-day survival between patients who received LD colistin and those who received LD colistin with nebulized colistin (adjusted hazard ratio [aHR]: 1.17, 95% confidence interval [CI]: 0.80–1.72, p = 0.418). Likewise, there were no significant differences in clinical response (aHR: 0.93, 95% CI: 0.66–1.31, p = 0.688), microbiological response (aHR: 1.21, 95% CI: 0.85–1.73, p = 0.279), or nephrotoxicity (aHR: 1.14, 95% CI: 0.79–1.64, p = 0.492) between the two treatment groups. No significant adverse events related to nebulized colistin were reported. These findings suggest that the addition of nebulized colistin may not offer additional benefits in terms of 30-day survival, clinical or microbiological response, or nephrotoxicity in these patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.
- Epidemiological and Innovative Research Group of Infectious Diseases (EIRGID), Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.
- Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
- Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
- Department of Medicine, Nakornping Hospital, Chiang Mai 50180, Thailand.
- Department of Pharmacy, Nakornping Hospital, Chiang Mai 50180, Thailand.
ORCID-Profile: Wasan Katip, Purida Wientong
Förderung
- Chiang Mai University
Zitieren
APA
Katip, W., Rayanakorn, A., Sornsuvit, C., Wientong, P., Oberdorfer, P., Taruangsri, P., & Nampuan, T. (2024). High-Loading-Dose Colistin with Nebulized Administration for Carbapenem-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients: A Retrospective Cohort Study. Antibiotics, 13(3), 287. https://doi.org/10.3390/antibiotics13030287
Vancouver
Katip W, Rayanakorn A, Sornsuvit C, Wientong P, Oberdorfer P, Taruangsri P, et al. High-Loading-Dose Colistin with Nebulized Administration for Carbapenem-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients: A Retrospective Cohort Study. Antibiotics. 2024;13(3):287. doi:10.3390/antibiotics13030287
BibTeX
@article{Katip2024,
author = {Katip, Wasan and Rayanakorn, Ajaree and Sornsuvit, Chuleegone and Wientong, Purida and Oberdorfer, Peninnah and Taruangsri, Puntapong and Nampuan, Teerapong},
title = {High-Loading-Dose Colistin with Nebulized Administration for Carbapenem-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients: A Retrospective Cohort Study},
journal = {Antibiotics},
year = {2024},
volume = {13},
number = {3},
pages = {287},
doi = {10.3390/antibiotics13030287}
}
EUVIMED